<DOC>
	<DOCNO>NCT00656643</DOCNO>
	<brief_summary>The purpose study determine safety efficacy ocular sirolimus ( rapamycin ) formulation various dose patient diabetic macular edema .</brief_summary>
	<brief_title>Dose Ranging Study Ocular Sirolimus ( Rapamycin ) Formulation Patients With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Inclusion Criteria include limited : Diagnosed diabetes mellitus Macular edema secondary diabetic retinopathy Visual acuity 20/40 20/200 study eye Exclusion Criteria include limited : Any ocular disease could compromise vision study eye Any follow treatment study eye within 90 day prior study start : intravitreal injection ; posterior subtenons steroid ; focal/grid macular photocoagulation ; intraocular surgery Capsulotomy study eye within 30 day prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>